Exploring a new treatment for triple-negative breast cancer using secretions from mammary cells.
The mammary cell secretome as a novel biologic for triple-negative breast cancer
This study is exploring how special substances from the milk-producing cells of cancer-resistant animals might help treat triple-negative breast cancer by killing cancer cells without harming healthy ones, with the goal of creating safer treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-10995271 on NIH RePORTER |
What this research studies
This research investigates the potential of bioactive factors secreted by mammary cells from cancer-resistant mammals to treat triple-negative breast cancer (TNBC). The approach involves studying how these secretions can induce cell death in TNBC cells while sparing normal breast cells, as well as testing their effects in mouse models. By characterizing these secretions further, the research aims to develop non-toxic therapies that could prevent or treat aggressive forms of breast cancer. Patients may benefit from innovative treatment options that are less harmful than current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who are seeking alternative treatment options.
Not a fit: Patients with other types of breast cancer or those who are not diagnosed with breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective, and non-toxic therapies for patients with triple-negative breast cancer.
How similar studies have performed: While the specific approach of using mammary cell secretions is novel, similar strategies targeting cancer suppression through biological factors have shown promise in other studies.
Where this research is happening
Ithaca, United States
- Cornell University — Ithaca, United States (Active)
Researchers
- Principal investigator: Harman, Rebecca M — Cornell University
- Study coordinator: Harman, Rebecca M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.